Skip to main content
OpenTrials
Completed

NCT Number: NCT02913794

Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Diseases Dyslipidemias Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Severance Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
  • Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
  • Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration

Exclusion criteria

  • Patients being hospitalized
  • Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
  • Patients who have more than 400mg/dl triglyceride(TG) at the registration time

Treatment and study plan

Primary outcomes

  1. Co-relation between blood pressure and dyslipidemia

    Time frame: 12 weeks

    Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease

Sponsors and collaborators

Lead sponsor

Boryung Pharmaceutical Co., Ltd

Industry

Registry information

Official study title

A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments

Acronym: FIMARO

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Sep 26, 2016
Registry last updated
Jun 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.